Development of LRRK2 Inhibitors for the Treatment of Parkinson’s Disease

Development of LRRK2 Inhibitors for the Treatment of Parkinson’s Disease

From Christensen, K. V. et al., In Progress in Medicinal Chemistry; Witty, D. R. and Cox, B., Eds., 2017, Elsevier: Amsterdam, Vol. 56, Ch.2, pp 37–80

< Back to all news